Stock Updates

Is this Large Market Cap Stock target price reasonable for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)?

The company in question is, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) currently with a stock price of 29.13 (-3.22% today). The market cap for Ionis Pharmaceuticals, Inc. is 3639.69, and is in the sector Healthcare, and Drug Manufacturers – Other industry. The target price for Ionis Pharmaceuticals, Inc. is 40.73. Currently Ionis Pharmaceuticals, Inc. is trading with a P/E of *TBA, and a forward P/E of *TBA. Average volume for Ionis Pharmaceuticals, Inc. is 2321.56 and so far today it is 1189232.

Performance in the last year for Ionis Pharmaceuticals, Inc. has been *TBA. For EPS growth, Ionis Pharmaceuticals, Inc. has seen a growth of -122.60%, and is looking to grow in the next year to 11.70%. More long term stats show that EPS growth has been -3.60% over the last five years and could be 41.00% for the next five years. Ionis Pharmaceuticals, Inc. has seen sales growth quarter over quarter at -68.00%, with EPS growth quarter over quarter at -263.90%. The 20-day simple moving average is -12.27%, with the 200-day simple moving average coming to -14.23%.

Since the IPO date for Ionis Pharmaceuticals, Inc. on the 5/17/1991, Ionis Pharmaceuticals, Inc. has seen performance year to date to be -40.03%. With Ionis Pharmaceuticals, Inc. trading at 29.13, the dividend yield is *TBA, and the EPS is -1.89.

So could Ionis Pharmaceuticals, Inc., be undervalued? Well as said before P/E is *TBA. The PEG is *TBA, P/S is 20.68 and the P/B is at 32.72. The P/cash is 5.41, with P/free cash flow at *TBA.

Ionis Pharmaceuticals, Inc. ability to deal with debt shows that the current ratio is 6.3, and the quick ratio is 6.2. This is with long term debt/equity at 4.28, and total debt/equity at 4.36.

In terms of margins, Ionis Pharmaceuticals, Inc. has a gross margin of -68.40%, an operating margin of *TBA and a profit margin of *TBA.Payout ratio for Ionis Pharmaceuticals, Inc. is *TBA. Return on assets come to -25.10% with return on investment coming to -11.30%.

Insider ownership for Ionis Pharmaceuticals, Inc., is at 0.20% and institutional ownership comes to 91.60%. Outstanding shares are at 120.92. While shares float is 119.99. The float short is currently 10.56%, and short ratio is 5.46.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Stephen Butters

Leave a Comment